The Nanopass 34G pen needle is intended for use with a pen injector device for the subcutaneous injection of drugs including insulin and human growth hormone.
Diabetes patients have long been in search of less painful1 insulin injection.
Terumo has made this possible with advanced Nanopass 34G – the world's thinnest double tapered pen needle2 with a diameter of only 34G. The world's first3 34G!
Nanopass 34G is 22% thinner than 32G.
Pain is primarily related to needle thickness. There are 100-200 pain receptors per cm² human skin surface. Nanopass 34G decreases the probability of touching the pain receptors and therefore makes the insulin injection less painful.1
Nanopass 34G causes less skin trauma than larger needle sizes, which results in less pain.1
The unique asymmetric bevel4 of Nanopass 34G cuts the skin instead of puncturing it.
This decreases the resistance while penetrating the skin. Another step towards less painful1 insulin injection.
The patented slim double tapered needle shape4 reduces the insulin injection force significantly.
Although the needle tip is 34G, Nanopass 34G provides less injection force than a conventional 32G pen needle.2
Nanopass 34G combines less painful1 injection with easy handling.
The brands listed are the property of the named companies.
1 Asakura T., Seino H., 2013, Jpn J Med Pharm Sci 69(1): 137-146. & Asakura T., 2013, Jpn J Med Pharm Sci 69(1): 147-155.
2 Based on research by Terumo Corporation in May 2017.
3 Terumo Corporation has launched Nanopass 34G in September 2012.
4 Patented technology.
Our sales representatives are here for you
Didn't find your product?